Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?

Adam Fundytus, Richard Sullivan, Christopher M. Booth*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)353-354
Number of pages2
JournalSeminars in Oncology
Volume47
Issue number6
DOIs
Publication statusPublished - Dec 2020

Cite this